Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) Other Non Operating Income (2020 - 2025)

Avidity Biosciences' Other Non Operating Income history spans 6 years, with the latest figure at -$477000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 337.31% year-over-year to -$477000.0; the TTM value through Dec 2025 reached -$1.9 million, down 683.47%, while the annual FY2025 figure was -$1.9 million, 683.47% down from the prior year.
  • Other Non Operating Income reached -$477000.0 in Q4 2025 per RNA's latest filing, down from -$380000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $201000.0 in Q4 2024 to a low of -$651000.0 in Q2 2025.
  • Average Other Non Operating Income over 5 years is -$145200.0, with a median of -$73500.0 recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: crashed 8000.0% in 2023, then soared 291.43% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$46000.0 in 2021, then soared by 60.87% to -$18000.0 in 2022, then crashed by 483.33% to -$105000.0 in 2023, then skyrocketed by 291.43% to $201000.0 in 2024, then crashed by 337.31% to -$477000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNA's Other Non Operating Income are -$477000.0 (Q4 2025), -$380000.0 (Q3 2025), and -$651000.0 (Q2 2025).